{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-128050","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.754709+00:00","generated_at":"2026-06-21T02:36:09.972007+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Black Diamond Therapeutics changes Chairman; Robert Ingram resigns, Mark Velleca appointed","bullets":["Robert A. Ingram resigned as Chairman and Board member effective Dec 13, 2022; no disagreement with company.","Mark A. Velleca, M.D., Ph.D. appointed Chairman of the Board on Dec 15, 2022.","Board size reduced from 10 to 9 members upon Ingram's resignation.","Velleca has been a board member since Aug 2021, formerly CEO of G1 Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-128050","json":"https://secwatch.observer/filing/0001104659-22-128050.json","markdown":"https://secwatch.observer/filing/0001104659-22-128050.md","text":"https://secwatch.observer/filing/0001104659-22-128050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/0001104659-22-128050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/tm2232856d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:36:09.972007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"109798028f","claim":"Robert A. Ingram resigned as Chairman of the Board at Black Diamond Therapeutics, Inc..","evidence_excerpt":"On December 13, 2022, Robert A. Ingram notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position of Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/0001104659-22-128050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"43c2c95ac8","claim":"Mark A. Velleca was appointed as Chairman of the Board at Black Diamond Therapeutics, Inc..","evidence_excerpt":"On December 15, 2022, upon the recommendation of the NCG Committee, the Board appointed current Board member Mark A. Velleca, M.D., Ph.D. to serve as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/0001104659-22-128050-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}